lenvatinib,pembrolizumab
eisai pharmaceutical,merck
['gyn', 'keynote-775', 'lenva', 'pembro']
data on next line of therapy from the phase 3 study 309/keynote-775 trial emphasized the benefit of lenvatinib plus pembrolizumab for advanced endometrial cancer. #gyncsm #asco22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.